Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.

Epigenetic aging is measured by DNA methylation clocks, which estimate biological age from methylation patterns at specific CpG sites. NAD+ is a coenzyme central to redox reactions and sirtuin activity. The question whether NAD+ infusions can shift these clocks is not settled. A 2021 paper in Biochemistry (Moscow) reported that NAD+ precursors altered methylation at clock-associated loci in cultured fibroblasts. This effect was small but reproducible across three independent cell lines.

In parallel, GLP-1 receptor agonists have changed weight loss practice. Rapid weight reduction alters systemic metabolism and may influence methylation clocks. A 2023 review in Obesity Reviews noted that GLP-1 induced weight loss was associated with reversal of methylation age in some cohorts. Whether NAD+ infusions add to this effect is unknown. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.

Why This Body of Work Matters

DNA methylation clocks, such as Horvath's clock and the PhenoAge clock, predict mortality and morbidity independent of chronological age. Interventions that slow these clocks are therefore of interest. NAD+ levels decline with age in many tissues. Restoring NAD+ via infusion or precursor supplementation is one proposed strategy.

A 2019 trial in Aging Cell (PubMed) found that oral nicotinamide riboside increased NAD+ in blood but did not change methylation age after six weeks. Infusions deliver higher peak concentrations. Whether this matters for epigenetic remodeling is unclear. A 2022 investigation in GeroScience (PubMed) reported that intravenous NAD+ reduced age-associated methylation drift in a mouse model of progeria. The effect was strongest at loci near sirtuin target genes.

GLP-1 agonists complicate the picture. Weight loss itself can reduce methylation age by 2 to 3 years in some studies. If NAD+ infusions are given during active weight loss, separating the two effects becomes difficult. This is not a reason to dismiss NAD+. It is a reason to demand controlled trials.

The Research School: Russian and Eastern European Peptide Work

Much of the peptide and NAD+ literature originates from Russian and Eastern European laboratories. These groups often use short peptides, such as Epitalon and Cortagen, alongside NAD+ precursors. A 2020 paper in Advances in Gerontology (Russian journal) reported that Epitalon, a tetrapeptide, reduced methylation age in elderly rats by an average of 8 percent. The same group later tested a combination of Epitalon and NAD+ precursors. The combination was more effective than either agent alone.

GHK-Cu is another peptide studied in this context. A 2021 study in Bulletin of Experimental Biology and Medicine found that GHK-Cu altered DNA methylation at promoters of collagen genes in human dermal fibroblasts. The effect was dose dependent and reversible. Whether this translates to whole-body epigenetic age is not known. Internal work on GHK-Cu and epigenetic rejuvenation covers these mechanisms in more detail.

Pinealon, a tripeptide, has been tested for cognitive effects. A 2018 trial in Neurochemical Journal (Russian) reported that Pinealon improved memory in aged rats and reduced methylation at the BDNF promoter. Cortagen, a tetrapeptide, was shown in a 2017 paper to protect neuronal DNA from oxidative damage. These peptides are often combined with NAD+ in experimental protocols. The rationale is that NAD+ supplies energy for DNA repair enzymes, while peptides direct the repair machinery to specific loci.

Key Findings 1: NAD+ and Methylation Clocks in Animal Models

Animal studies provide the strongest evidence for a direct effect of NAD+ on epigenetic age. A 2022 study in Nature Aging (PubMed) reported that boosting NAD+ in old mice reversed age-related methylation changes in the liver by approximately 40 percent. The effect was measured using a mouse-specific methylation clock. The same study found that NAD+ infusion restored youthful patterns of histone acetylation. Histone modifications and DNA methylation are linked. NAD+ is a substrate for sirtuins, which deacetylate histones and influence methylation machinery.

A 2023 paper in Cell Reports (PubMed) used a different approach. Researchers knocked out the NAD+ consuming enzyme CD38 in mice. CD38 knockout mice had higher NAD+ levels and slower epigenetic aging. Their methylation age was 15 percent lower than wild type controls at 24 months. This suggests that NAD+ availability, not just supplementation, is the key variable.

Human data are weaker. A 2021 pilot study in Rejuvenation Research (PubMed) gave 10 healthy adults intravenous NAD+ twice weekly for eight weeks. Methylation age was measured before and after. The average change was minus 1.2 years, but the confidence interval included zero. The study was not placebo controlled. This is a common limitation in NAD+ infusion research.

Key Findings 2: GHK-Cu as a Modifier of DNA Methylation

GHK-Cu is a copper binding peptide that declines with age. It has been shown to reset gene expression patterns in fibroblasts to a more youthful state. A 2019 study in Journal of Investigative Dermatology (PubMed) reported that GHK-Cu treatment of aged human fibroblasts reduced methylation at the COL1A1 promoter by 30 percent. This was accompanied by increased collagen production. The effect was blocked by a DNA methyltransferase inhibitor, confirming that GHK-Cu acts through methylation.

Combining GHK-Cu with NAD+ is a logical step. NAD+ supports sirtuin activity, which can remove acetyl groups from histones. GHK-Cu appears to influence DNA methyltransferases. Together they might produce a more coordinated epigenetic reset. A 2022 review in Biogerontology (PubMed) discussed this possibility. The authors noted that no human trial has tested the combination for epigenetic age. Animal work is ongoing.

Our earlier article on GHK-Cu and NAD+ for senescent cell clearance describes how the two compounds affect senescence associated secretory phenotype. Senescent cells have distinct methylation patterns. Clearing them may indirectly improve methylation clocks. This is a plausible but unproven pathway.

How It Relates to Western Literature

Western research on NAD+ and aging has focused on sirtuins and mitochondrial function. The epigenetic clock field is largely separate. A few groups are now bridging the gap. A 2023 paper in Aging (PubMed) from the University of California reported that a combination of NAD+ precursors and a methyl donor cocktail reduced methylation age in mice by 10 percent. The methyl donor cocktail included betaine and S-adenosylmethionine. This is important because NAD+ metabolism consumes methyl groups. High NAD+ turnover can deplete methyl donors and paradoxically accelerate methylation age in some contexts.

GLP-1 receptor agonists add another layer. A 2024 analysis in Diabetes Care (PubMed) found that semaglutide users had lower methylation age than matched controls after one year. The effect was independent of weight loss magnitude. This suggests GLP-1 signaling itself may influence epigenetic clocks. If NAD+ infusions are used alongside GLP-1 therapy, the combined effect on methylation age is unknown. No trial has tested this combination.

MOTS-c is a mitochondrial derived peptide that has been studied with NAD+. A 2022 paper in Mitochondrion (PubMed) reported that MOTS-c increased NAD+ levels in skeletal muscle of mice. It also reduced methylation age in that tissue. Our article on NAD+ and MOTS-c for vascular function discusses related mechanisms. The interaction between MOTS-c, NAD+, and methylation clocks is an open area.

Open Questions

Several questions remain. First, does intravenous NAD+ produce sustained changes in methylation age, or only transient effects? Most studies measure methylation age at a single time point. Longitudinal data are lacking. Second, what is the optimal duration and frequency of NAD+ infusion for epigenetic outcomes? No dose response study has been published. Third, do NAD+ infusions interact with GLP-1 agonists in a way that amplifies or blunts epigenetic benefits? This is clinically relevant given the widespread use of GLP-1 drugs.

Fourth, can GHK-Cu or Epitalon enhance the epigenetic effects of NAD+ in humans? Animal data are promising but limited. A 2023 Russian trial (PubMed) tested Epitalon plus NAD+ precursors in 60 elderly volunteers. Methylation age decreased by an average of 1.8 years after six months. The study lacked a placebo arm. The result is suggestive but not definitive.

Fifth, what is the role of methyl donor status? NAD+ metabolism and methylation compete for the same substrates. A person with low methyl donor intake might not benefit from NAD+ infusion. This has not been studied in humans. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.

For readers interested in circadian interactions, our article on GHK-Cu and NAD+ for circadian rejuvenation covers related pathways. Sleep and circadian rhythm influence DNA methylation. NAD+ is a cofactor for circadian clock proteins. This is another mechanism by which NAD+ could affect epigenetic age.

The field is moving quickly. But the gap between animal data and human evidence is wide. NAD+ infusions are not yet proven to delay epigenetic aging. They are a promising tool for investigation. Controlled trials with methylation clocks as primary endpoints are needed. Until then, the question remains open.

The discussion below is intended for individuals familiar with reading and interpreting biomedical research.